Results 191 to 200 of about 96,322 (259)

Acquired <i>EML4-ALK</i> fusion and <i>BRAF</i> V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report. [PDF]

Front Oncol
Zhang R, Li J.
europepmc   +1 more source

ALK-negative anaplastic large cell lymphoma in pediatric and adolescent patients: a mini-review. [PDF]

Front Oncol
Devine KJ, Stokke J, Lim MS, Schwartz LF.   +3 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

A Case of an Inflammatory Myofibroblastic Tumor Harboring a Novel STRN3::ALK Fusion. [PDF]

Pathol Int
Yamamoto K, Miyata R, Kunieda J, Togashi Y, Baba S, Asakawa A, Okubo K, Yamashita K, Ohashi K, Takeuchi K.   +9 more
europepmc   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, EarlyView.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK⁺ ALCL. [PDF]

Exp Hematol Oncol
Li G, Wang J, Ye S, Zhou L, Sun Y, Li B, Zhao Y, Ding Y, Zeng Y, Xue B, Wang G, Wang F, Luo X, Liang A, Weisberg EL, Zhang W, Lu W, Yang J.   +17 more
europepmc   +1 more source

Need to Assess On‐Demand Versus Continuous Treatment in Allergic Rhinitis in ARIA‐EAACI Guidelines

Allergy, EarlyView.
Jean Bousquet, Bernardo Sousa‐Pinto, Maria J. Torres, Mario Morais‐Almeida, Ludger Klimek, Giorgio Ciprandi, Robert Naclerio, Torsten Zuberbier   +7 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer. [PDF]

Oncologist
Li X, Yasin F, Pavlick DC, Ross JS, Cecchini M.   +4 more
europepmc   +1 more source

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

Cancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao, Yuqiang Liu, Mingxuan Xie, Zhiming Ye, Hong Huang, Maojin Yao, Feng Zhou, Jianzhu Zhao, Jun Tang   +8 more
wiley   +1 more source